论文部分内容阅读
目的 分析分化型甲状腺癌13 1I治疗后扫描假阳性摄取的常见部位和摄取机制。方法 分化型甲状腺癌患者3 46例 ,口服治疗剂量13 1I后 7天进行全身13 1I扫描 ,根据临床症状、体征、13 1I全身扫描结果、血清Tg水平和其他影像学检查结果 ,判断13 1I的摄取是否为假阳性摄取。结果 胃肠道假阳性摄取 65例 ,肺部假阳性摄取 12例 ,双侧乳腺假阳性摄取3例 ,两侧腋下汗腺假阳性摄取 1例 ,肝脏显影 2 5 3例。结论 13 1I治疗后扫描发生假阳性摄取常见部位主要为胃肠道、肺部和肝脏 ;应注意甄别 ,避免使患者接受不必要的13 1I治疗。
Objective To analyze the common site of uptake and uptake of false positives in differentiated thyroid carcinoma after 131I treatment. Methods Three hundred and sixty-six patients with differentiated thyroid cancer and 13 1I 7 days after oral administration of 131I were enrolled. According to clinical symptoms, signs, whole-body scan of 13I, serum Tg level and other imaging findings, Whether the intake is a false positive. Results There were 65 cases of false positive gastrointestinal tract uptake, 12 cases of false lung uptake, 3 cases of bilateral false positive breasts uptake, 1 case of underarm sweat gland false positives on both sides, and 235 cases of liver development. CONCLUSIONS: The common site of false positive uptake after 1I treatment is mainly gastrointestinal tract, lung and liver. Care should be taken to avoid patients receiving unnecessary 131I treatment.